Renu Vaish

Chief Regulatory Officer

Renu Vaish has served as our Chief Regulatory Officer since July 2023, leading Global Regulatory Affairs and Quality. Ms. Vaish is an accomplished executive with a demonstrated track record of more than 25 years in global regulatory strategy across diverse organizations, for multiple therapeutic areas including rare disease, cell therapy, immuno-oncology, and oncology. Prior to Ambrx, Ms. Vaish held leadership positions with companies such as SpringWorks, Kite/Gilead, Atara, Merck, and Celgene overseeing the development of novel medical entities for several soon-to be or FDA-approved drugs. She worked cross functionally from pre-clinical to post-approval on products including Velcade, Abraxane, Revlimid, Tecartus, and Keytruda.

Ms. Vaish holds a Bachelors of Science degree from Concordia University and a Master of Science degree in Regulatory Affairs and Health Policy from the Massachusetts College of Pharmacy and Health Sciences. Separately, Ms Vaish is a member of the Board of Trustees for the Cancer Hope Network and is on the Board of Advisors for the Philadelphia Life Science Cares.